AQAL Integral Investing

AQAL Capital invests in state-of-the-art exponential technology companies which have the potential for integral impact, including substantial growth, while implementing the UN SDGs within the Planetary Boundaries. We focus on seed and early-stage companies. Their leadership team must be strong, their technology must be proven, and should have a short runway to cash flow break-even. Our regional focus is the European Union with the main emphasis on DACH (Germany, Austria, Switzerland). A few selected investments are also made in the San Francisco Bay Area. According to our Integral Investing philosophy, the business models of our investees must be transferable to other countries, be scalable to market leadership, and deliver sustainable and risk-adjusted returns on multiple bottom lines as defined by our 6Ps: Parity of People, Planet, and Profit — with Passion and Purpose. Given our investing expertise, background, and entrepreneurial experience, we are focusing on three main sectors of innovation for life in the 21st century: Exponential Technology & Digital Evolution: Internet Infrastructure, Artificial Intelligence, B2B IT Solutions, Digital Design Green Technology: Renewable Energy, Energy Efficiency, CleanTech, Circular Economy Life in the 21st century: Future Mobility, Nutrition & Agro, Med Tech, Media & Entertainment Tech

Mariana Bozesan Ph.D

Founder and Partner

Tom Schulz

Co-Founder and Managing Partner

4 past transactions

DNTOX

Seed Round in 2023
We are building up a bioanalytical testing laboratory for animal-free screening of chemicals, regarding their potential to disturb brain development and cause developmental neurotoxicity (DNT). Our in vitro testing battery is based on human cell models and enables chemical screening in a high-content and medium-throughput fashion. Furthermore, it is supported by an in-house developed software, using artifical intelligence. We support our customers during the identification of safe lead structures during substance development, as well as the safety assessment during approval and re-approval processes of chemicals. With our innovation, we want to realize our company vision: Safe chemicals without animal experiments!

PhysioCue

Seed Round in 2019
PhysioCue is a medical device company that has developed anti-hypertensive and migraine/headache medical devices which have been clinically proven to immediately reduce the high blood pressure of hypertensive patients and shown to relieve migraine/headache pain. These devices are non-invasive and work by controlled cold therapy to trigger the carotid artery baroreceptor reflex. Unlike drug treatments and invasive procedures, their PhysioCue therapy is efficient, safe, easy to use, and has none of the side effects associated with anti-hypertensive drugs. PhysioCue is also developing a wearable mobile health device.

SURGITENT

Seed Round in 2017
Surgical Isolation - Redefined

NDC Data Centers

Seed Round in 2016
NDC Data Centers realizes cost-effective construction and operation through sustainability at the technological, commercial and building level. NDC integrates award-winning proprietary cooling technology with future-proof architecture, cutting edge technical design, and lean construction project delivery methods. NDC offers green, sustainable and energy efficient data centers with the goal of drastically reducing the resource requirement for the exponential increase of IT hardware need. The innovative deployment model, which comprises energy services, real estate leasing and facility management, is tailored to the customers’ needs.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.